Skip to main content
Innoviva, Inc. logo

Innoviva, Inc. — Investor Relations & Filings

Ticker · INVA ISIN · US45781M1018 LEI · 549300ACOX4QTBES6535 US Financial and insurance activities
Open in API
Filings indexed 1,226 across all filing types
Latest filing 2011-11-03 Director's Dealing
Country US United States of America
Listing US INVA

About Innoviva, Inc.

https://www.inva.com/

Innoviva, Inc. is a diversified holding company that manages a portfolio of royalty-generating assets and operates a commercial-stage biopharmaceutical platform. The company's core royalty business is centered on respiratory therapies, providing a stable cash flow. Through its subsidiary, Innoviva Specialty Therapeutics, it focuses on developing and commercializing innovative treatments for patients in critical care and with infectious diseases. Innoviva's strategy involves leveraging its financial assets to invest in healthcare opportunities with high unmet medical needs, aiming to advance differentiated therapies and build a diverse portfolio of healthcare assets.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2011-11-03 English
10-Q Filing
Interim / Quarterly Report Q3 2011
2011-11-02 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions an oral presentation by GlaxoSmithKline at a medical conference, attached as an exhibit, but does not contain financial statements or detailed financial data. The document is short (3293 characters) and primarily serves to announce the event and attach the presentation. There is no indication of quarterly or annual financial results, management changes, or other specific report types. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-10-27 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated October 27, 2011. It specifically mentions that it includes a press release regarding financial results for the quarter ended September 30, 2011. The document states that the information is being furnished and is not "filed" for purposes of Section 18, indicating it is an announcement rather than a full financial report. The length of the document is 2706 characters, which is relatively short and consistent with a press release or earnings announcement rather than a full quarterly report. The key phrase "issued a press release regarding its financial results for the quarter" strongly suggests this is an Earnings Release (ER) type document, which is the initial announcement of quarterly financial results with key highlights only. Therefore, the appropriate classification is Earnings Release (ER).
2011-10-27 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes presentations of clinical study posters at a medical congress, attached as exhibits, and does not contain financial statements or detailed financial analysis. It is not an earnings release, annual report, or interim report. The document is an announcement of other events related to clinical study results and presentations, typical for an 8-K filing. Given the nature of the content and the form type, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2011-09-26 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The content describes an announcement about the European Commission granting marketing authorization for a drug, and it includes a press release as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2557 characters) and primarily serves as a regulatory announcement of an event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2011-09-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.